Merck & Co. insider trading
Every open-market purchase and sale by Merck & Co.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Merck & Co.’s insiders pay?
From February 24, 2010 to August 13, 2026, 43 insiders reported 5 open-market purchases and 151 sales not made under a pre-set plan in Merck & Co. Twelve months after each purchase was reported, the shares were +17.8% against the S&P 500 on average (median +23.3%), over 5 purchases with a full year of prices; 80% beat the index. After sales, the shares moved −7.6% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 16, 2011 into $27,157 by November 2, 2026, +6.8% a year. It held shares 17% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $19,202 (+4.4% a year), and held throughout $82,565 (+14.9%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Deluca Richard R. | EVP&Pres, Merck Animal Heallth | 0 | — | — | 11 | −0.6% (8) | August 12, 2026 |
| Frazier Kenneth C | Executive Chair | 1 | +23.3% (1) | 100% | 8 | −4.4% (8) | November 8, 2022 |
| Mizell Steven | EVP, Chief HR Officer | 0 | — | — | 8 | −13.6% (8) | February 2, 2024 |
| Oosthuizen Johannes Jacobus | President, U.S. Market | 0 | — | — | 7 | −15.0% (6) | February 6, 2026 |
| Weeks Wendell P | Director | 0 | — | — | 7 | −7.5% (7) | May 7, 2020 |
| Deese Willie A | Exe V-P & Pres. MMD | 0 | — | — | 6 | −1.8% (6) | February 11, 2015 |
| Karachun Rita A | Sr. VP Fince-Global Controller | 0 | — | — | 6 | −0.1% (6) | May 5, 2023 |
| Williams David Michael | EVP,Chief Info&Digital Officer | 0 | — | — | 6 | −10.4% (3) | August 7, 2026 |
| Zachary Jennifer | EVP, General Counsel | 0 | — | — | 6 | −19.3% (4) | August 13, 2026 |
| Bowles Richard S III | Exe VP&Chief Ethics & ComplOff | 0 | — | — | 5 | 0.0% (5) | May 10, 2012 |
| Davis Robert M | Chairman, CEO & President | 0 | — | — | 5 | −22.1% (4) | February 6, 2026 |
| Gerberding Julie L. | EVP, Chief Patient Officer | 0 | — | — | 5 | +5.4% (5) | November 3, 2021 |
| Guindo Chirfi | EVP, Access, Policy & Comms | 0 | — | — | 5 | — | August 13, 2026 |
| Wendell Peter C | Director | 0 | — | — | 5 | −12.3% (5) | February 6, 2017 |
| Chattopadhyay Sanat | Exe V-P & Pres. MMD | 0 | — | — | 4 | −8.7% (4) | November 1, 2022 |
| Clyburn Frank | EVP & Pres ? Human Health | 0 | — | — | 4 | +6.4% (4) | November 2, 2021 |
| Golestani Clark | EVP & Chief Info Officer | 0 | — | — | 4 | −5.7% (4) | August 10, 2016 |
| Kuhlik Bruce N | Exe V-P & Gen Counsel | 0 | — | — | 4 | −6.3% (4) | May 5, 2015 |
| Ambrose Adele D | Sr.V-P & Chief Comuns Officer | 0 | — | — | 3 | +5.1% (3) | October 29, 2015 |
| Barshay Stanley F | ExVP&PresConsHlthCare | 0 | — | — | 3 | −26.5% (3) | March 5, 2010 |
| Heller Bridgette P | Exe.VP & Pres.Con.Hlth.Care | 0 | — | — | 3 | +3.1% (3) | February 14, 2014 |
| Holston Michael J | EVP, General Counsel | 0 | — | — | 3 | −11.2% (3) | February 6, 2017 |
| Li Dean Y | Executive VP & President, MRL | 0 | — | — | 3 | −57.0% (1) | February 10, 2026 |
| Litchfield Caroline | EVP & CFO | 0 | — | — | 3 | −4.5% (2) | February 6, 2026 |
| Romanelli Joseph | President, Human Health Int?l | 1 | −13.0% (1) | 0% | 2 | −28.9% (2) | February 14, 2024 |
| Schechter Adam H | EVP & Pres-Global Human Health | 0 | — | — | 3 | −11.3% (3) | May 11, 2015 |
| Brun Leslie A | Director | 0 | — | — | 2 | −28.1% (2) | May 7, 2020 |
| Canan John | Sr.V-P Finc-Global Controller | 0 | — | — | 2 | −8.3% (2) | February 11, 2014 |
| Cech Thomas R | Director | 0 | — | — | 2 | −5.7% (2) | February 6, 2017 |
| Downing Cristal N | Chief Comm. & Public Afrs Ofcr | 0 | — | — | 2 | +27.5% (1) | November 12, 2025 |
| Glocer Thomas H | Director | 0 | — | — | 2 | +10.8% (2) | February 4, 2019 |
| Kohan Raul E | Exe V-P & Pres, Animal Health | 0 | — | — | 2 | −11.5% (2) | May 19, 2011 |
| Lazarus Rochelle B | Director | 0 | — | — | 2 | −19.8% (2) | November 2, 2016 |
| Smart Dalton E. III | SVP Fin. - Global Controller | 0 | — | — | 2 | +5.0% (1) | February 6, 2026 |
| Baker Douglas M Jr | Director | 1 | +27.5% (1) | 100% | 0 | — | February 7, 2025 |
| Kellogg Peter N | Exe V-P & CFO | 1 | +23.3% (1) | 100% | 0 | — | August 15, 2011 |
| Kidder C Robert | Director | 0 | — | — | 1 | −18.8% (1) | May 12, 2017 |
| Kim Peter S | Exe V-P & Pres, MRL | 0 | — | — | 1 | −21.0% (1) | November 6, 2012 |
| Maraldo David R. | EVP & Pres. MMD | 0 | — | — | 1 | — | August 7, 2026 |
| Perlmutter Roger M | Exe V-P & Pres, MRL | 0 | — | — | 1 | +2.0% (1) | November 8, 2018 |
When several insiders traded Merck & Co.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Merck & Co. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged +3.7% against the index. After 15 selling crowds, −1.6%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 31, 2026 | 5 selling | not yet | not yet | not yet |
| February 27, 2026 | 9 selling | −14.0% | +8.8% | not yet |
| February 28, 2025 | 3 selling | −15.5% | −16.3% | +18.9% |
| February 29, 2024 | 8 selling | −4.6% | −17.1% | −40.2% |
| November 30, 2022 | 8 selling | −1.9% | −2.3% | −17.9% |
| November 30, 2021 | 6 selling | +6.9% | +33.4% | +61.3% |
| October 30, 2020 | 3 selling | −13.1% | −25.5% | −16.2% |
| February 28, 2019 | 5 selling | −1.9% | +3.2% | −11.6% |
| November 30, 2018 | 4 selling | +1.3% | +0.7% | −1.4% |
| November 30, 2016 | 3 selling | +0.8% | −3.3% | −29.7% |
| October 30, 2015 | 3 selling | +1.0% | +2.3% | +6.6% |
| April 30, 2015 | 4 selling | −2.6% | −7.2% | −5.9% |